Flputnam Investment Management Co. Sells 12,619 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Flputnam Investment Management Co. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 62.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,493 shares of the biopharmaceutical company’s stock after selling 12,619 shares during the period. Flputnam Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $5,337,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Nvwm LLC grew its stake in Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after acquiring an additional 14 shares during the period. Howe & Rusling Inc. boosted its stake in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 15 shares during the last quarter. Willner & Heller LLC boosted its stake in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares during the last quarter. OLD Second National Bank of Aurora boosted its stake in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 15 shares during the last quarter. Finally, Sigma Planning Corp boosted its stake in Regeneron Pharmaceuticals by 4.1% during the 3rd quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 16 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:REGN opened at $698.74 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $76.39 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The firm’s 50-day moving average is $698.51 and its two-hundred day moving average is $868.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.86 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.